Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
982.29
+14.31 (+1.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
31
32
Next >
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
May 01, 2023
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro...
Via
Talk Markets
Where Regeneron Pharmaceuticals Stands With Analysts
May 01, 2023
Via
Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
April 27, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
Via
Benzinga
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
April 27, 2023
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 25
April 25, 2023
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 20
April 20, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
April 18, 2023
Via
Benzinga
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
April 26, 2023
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at...
Via
Benzinga
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
April 24, 2023
Via
Benzinga
The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio
April 20, 2023
With so many rumblings in the equities space, investors may be best served taking on the top blue-chip stocks to buy.
Via
InvestorPlace
Regeneron Pharmaceuticals Unusual Options Activity
April 12, 2023
Via
Benzinga
MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate
April 11, 2023
Via
Benzinga
Investing $1,000 In These 2 Top Stocks Would Be a Great Move
April 09, 2023
Both have beaten the market over the past year.
Via
The Motley Fool
Regeneron Pharmaceuticals Unusual Options Activity For April 05
April 05, 2023
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
April 03, 2023
Via
Benzinga
JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
March 31, 2023
Via
Benzinga
2 Top Growth Stocks That Could Soar This Spring
April 06, 2023
Exciting news on the way for both of these companies could send their stock prices screaming higher.
Via
The Motley Fool
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
April 03, 2023
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
April 03, 2023
Via
Benzinga
NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
March 31, 2023
Benchmark cut the price target for CuriosityStream Inc. (NASDAQ: CURI) from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in...
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For March 28
March 28, 2023
Via
Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
March 27, 2023
Via
Benzinga
Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
March 24, 2023
Via
Benzinga
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
March 30, 2023
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease.
Via
The Motley Fool
Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades'
March 28, 2023
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc.
Via
Benzinga
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug
March 27, 2023
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023
March 27, 2023
Via
Benzinga
Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday
March 27, 2023
UBS cut the price target for DISH Network Corporation (NASDAQ: DISH) from $27 to $10. UBS analyst John Hodulik downgraded the stock from Buy to Neutral. DISH Network shares fell 2.1% to $8.57 in...
Via
Benzinga
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
March 25, 2023
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.
Via
The Motley Fool
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.